{"id":"NCT02753946","sponsor":"Nabriva Therapeutics AG","briefTitle":"Safety and Efficacy of ZTI-01 (IV Fosfomycin) vs Piperacillin/Tazobactam for Treatment cUTI/AP Infections","officialTitle":"Randomized, Double-Blind, Comparative Study to Evaluate the Safety and Efficacy of ZTI-01 vs Piperacillin/Tazobactam in the Treatment of cUTI/AP Infection in Hospitalized Adults","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2016-04","primaryCompletion":"2017-01-12","completion":"2017-05-30","firstPosted":"2016-04-28","resultsPosted":"2018-12-11","lastUpdate":"2019-03-07"},"enrollment":465,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Urinary Tract Infection Symptomatic","Acute Pyelonephritis","Urinary Tract Infection Complicated"],"interventions":[{"type":"DRUG","name":"ZTI-01","otherNames":["disodium fosfomycin"]},{"type":"DRUG","name":"Piperacillin-tazobactam","otherNames":["piperacillin-tazobactam combination product"]}],"arms":[{"label":"ZTI-01","type":"EXPERIMENTAL"},{"label":"piperacillin tazobactam","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of the study is to demonstrate the safety and efficacy of ZTI-01 (IV fosfomycin) as non-inferior to piperacillin/tazobactam in overall success (clinical cure and microbiologic eradication) for the treatment of hospitalized patients with complicated urinary tract infections (cUTI) or acute pyelonephritis (AP).","primaryOutcome":{"measure":"Number of Patients With an Overall Success","timeFrame":"TOC Visit (Day 19)","effectByArm":[{"arm":"ZTI-01","deltaMin":119,"sd":null},{"arm":"Piperacillin Tazobactam","deltaMin":97,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":68,"countries":["United States","Belarus","Bulgaria","Croatia","Czechia","Estonia","Georgia","Greece","Hungary","Latvia","Lithuania","Poland","Romania","Russia","Slovakia","Ukraine"]},"refs":{"pmids":["30861061"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":233},"commonTop":["Alanine aminotransferase increased","Aspartate aminotransferase increased","Diarrhea","Hypokalemia","Nausea"]}}